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1. INTRODUCTION 
In recent years, in association with progress and 
innovation in the field of pharmaceutical technology, 
there has been an increasing effort to develop sustained 
release dosage forms for many drugs. Correspondingly, a 
growing number of new sustained release dosage forms 
have been submitted for regulatory approval. Prolonged 
release dosage forms have many advantages in safety 
and efficacy over immediate release drug products in that 
the frequency of dosing can be reduced, drug efficacy 
can be prolonged and the incidence and/or intensity of 
adverse effects can be decreased 1. The main approaches 
to prolong the gastric residence of the pharmaceutical 
dosage forms include bioadhesive delivery system, 
which adheres to the mucosal surface; and release the 
active contents in a controlled manner 2. 
Gums and mucilages of different sources and their 
derivatives represent a group of polymers widely used in 
pharmaceutical dosage forms. In recent years, a number 
of natural gums and mucilages have been evaluated for 
mucoadhesive drug delivery systems. This increased 
interest in natural polymer is due to their non-toxicity, 
cheap, easy availability, biodegradability and 
biocompatibility 3. Apart from their safety, these natural 
polysaccharides are capable of providing the comparable 
drug release profiles with currently available sustained 
release products in markets.  
Levamisole, marketed as the hydrochloride salt under  
the trade name Ergamisol (R12564), an  anthelmintic 
and immunomodulator belonging to a class of synthetic 
imidazo-thiazole derivatives. The low bioavailability 
(47%) and short biological half-life (4.4 to 5.6 h) of 
levamisole following oral administration favors the 
development of a sustained release formulation. The 
objective of the present research includes in vitro, Ex 
vivo and in vivo evaluation of mucoadhesive properties 
of purified polysaccharides from Terminalia bellerica 
gum by using Levamisole hydrochloride as a model 
drug. The formulated tablets were characterized and 
optimized 4. 
 
 
 
 
 
*Corresponding Author:   
Biswajit Das,  
Girijananda choudhury institute of pharmaceutical sciences 
Azara, Hathkhowapara, Guwahati, Assam, Pin-781017 
E. Mail: bapipm@gmail.com ,  
Cell No.: +91 9435902134 
 
 
ABSTRACT 
The present investigation deals with the development of mucoadhesive gastro retensive tablets of levamisole using 
polysaccharide isolated from Terminalia bellerica gum (TBG). The TBG polysaccharide was tested for acute toxicity and 
drug–excipient compatibility study. The tablet formulations with TBG were evaluated for physical characteristics like 
hardness, % friability, % drug content and weight variations. Dissolution study was conducted to characterize release 
mechanism of the formulation and data are fitted to various kinetic models. The mucoadhesive abilities were studied by 
different in vitro, Ex vivo and in vivo models. The in vitro release study showed that the optimized formulation exhibited 
highest correlation (R) value in the case of Korsemeyer–Peppas model and the release mechanism study proved that the 
formulation showed a combination of diffusion and erosion processes. The mucoadhesive properties of polysaccharide are 
comparable to synthetic polymer in all Ex vivo, in vitro and in vivo models.  There was a significant difference in the 
pharmacokinetic parameters (Tmax, Cmax, AUC0-∞, AUC0-t, AUMC, MRT, T1/2, Ka and Kel) of the optimized formulation as 
compared to standard marketed formulation, which proves the controlled release and mucoadhesive property of the isolated 
polysaccharide. 
Keywords- TBG polysaccharide, Scintigraphic,  X-Ray study, Korsemeyer–Peppas model 
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MATERIALS AND METHODS 
1.1. Materials 
Levamisole was kindly gifted by Wockhardt 
Limited, Baddi, India. Polyvinyl Pyrrolidine K-30 (PVP 
K-30) was obtained from Alembic, Vadodra, India. 
Other chemicals were purchased from S.D Fine 
Chemicals Ltd., Mumbai, India. All other chemicals and 
reagents used were of analytical grade. 
1.2. Extraction and purification of 
polysaccharide 
Dried gums were collected from the trunk bark of 
Terminalia belarica plant and separated from fungal 
affected and other foreign object present during 
collection. They were converted into small pieces using a 
hammer. The pieces were then dried in oven dryer 
maintained between 40°C to 50°C for 72 h to obtain dry 
mass which were milled with a grinder to get the dry 
powder. The dried powder was passed through sieve 
number 40# and stored in an airtight container. The 
powder (1 kg) was extracted with boiling water three 
times. The aqueous extract was filtered through 
Whattman filter paper. The filtrate was concentrated in a 
rotary evaporator under reduced pressure, and then 
centrifuged at 3000 rpm for 15 min. The supernatant was 
precipitated with three volumes of acetone, and stored 
overnight at 4°C. The precipitate was collected and 
washed again three times with acetone to get crude 
polysaccharide (60.4 g). The crude polysaccharide was 
subjected to DEAE- Sephadex A-50 column 
chromatography, washed with H2O and eluted with 1.0 
M NaCl solution. Most of the pigments were absorbed in 
the column. The Elutes collected were concentrated 
under reduced pressure to an appropriate volume, and 
then dialyzed against distilled water. The remaining 
portion was lyophilized to afford total purified 
polysaccharide 5. 
1.3. Acute toxicity study of polysaccharide 
Healthy male and female Swiss albino mice (8 
weeks) were used for the acute oral toxicity study. They 
were breed and reared at the animal house of the 
institution. The animals were housed in polypropylene 
cages and provided with bedding of clean paddy husk. 
The animals were acclimatized to laboratory conditions 
for one week prior to the experiment. The temperature in 
the animal house was maintained at 25 ±20C with a 
relative humidity of 30–70% and illumination cycle set 
to 12 h light and 12 h dark. The mice were fed with 
standard laboratory pelleted feed (M/s Gold Mohur 
Foods and Feeds Ltd. Bangalore, India). All the mice of 
both the sexes were fasted overnight before 
experimentation and were allowed to take food one hour 
after the experiment. Purified polysaccharide of TBG 
was administered orally at a dose of 2000 mg/kg body 
weight in distilled water. The animals were observed for 
any mortality and morbidity (convulsions, tremors, and 
grip strength and pupil dilatation) at an interval of 12 h 
for 14 days. This study was approved by the Animal 
Ethics Committee of Girijananda chowdhury institute of 
pharmaceutical sciences (CPCSEA 
Regn.No.1372/C/10/2013/CPCSEA, study approval No-
GIPS/IAEC/10) 6 
1.4. Pre formulation study 
1.4.1. Drug–excipient compatibility study by DSC 
A differential scanning calorimetry (JADE DSC, 
Perkin Elmer, USA) was used to study the thermal 
analysis of drug–excipient compatibility. Firstly, binary 
mixtures of levamisole and polysaccharide (in 1:1 
mass/mass ratio) were prepared by using physical 
mixture technique. The drug–excipient mixture was 
scanned in the temperature range of 50–300°C under an 
atmosphere of nitrogen. The heating rate was 20 °C /min 
and the obtained thermo grams were observed for any 
type of interaction 7. 
1.4.2. Drug–excipient compatibility study by FT-IR 
spectroscopy 
FT-IR spectra were recorded on a Bruker 
spectrophotometer (Model-220, Germany) using KBr 
discs in the range of 4000–4500 cm‾1. FT-IR analysis has 
been performed using sample of levamisole with 
polysaccharide at 1:1 mass/mass ratio 8 
1.5. Formulation of tablet 
Terminalia bellerica gum polysaccharide based 
mucoadhesive tablets of levamisole were prepared by 
wet granulation method using different compositions as 
per Table 1 All the ingredients were screened through 
sieve no. 60 and then blended (except magnesium 
stearate) for 15 min. A blend of all ingredients was 
granulated with 95% isopropyl alcohol. The wet masses 
were passed through sieve no. 12 and the resulting 
granules were dried at 40°C. The dried granules were 
again passed through sieve no. 22.   Finally magnesium 
stearate was added and mixed for 5min. The micro-
meritic studies were carried out for all the granules. The 
results of angle of repose, Carr’s Index and Hausner ratio 
indicated that the granules possess good flow property 
and good packing ability.  Tablets were compressed on a 
8-station Mini Press-I rotary tablet compression machine 
(Shakti Pvt Ltd) fitted with 8-mm flat-shaped punches 
using sufficient compression force to obtain a hardness 
of 4 to 5 Kg/cm² containing 50 mg of levamisole per 
Tablet. Manufacturing defects were observed in tablets 
like capping, lamination and chipping 9. 
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Table 1: Formulae code of levamisole mucoadhesive tablet 
Ingredients Weight of Ingredients mg/tablet 
 F10 F15 F20 F25 F30 F35 F40 F45 F50 
Levamisole 50 50 50 50 50 50 50 50 50 
TBP 16 24 32 40 48 56 64 72 80 
Polyvinyl pyrollidone (K 30) 5 5 5 5 5 5 5 5 5 
Microcrystalline cellulose 84.2 76.2 68.2 60.2 52.2 44.2 36.2 28.2 20.2 
Magnesium stearate 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 
Talc 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6 
Total Tablet weight 160 160 160 160 160 160 160 160 160 
 
1.6. Evaluation of tablets 
Thickness of each tablet was measured in mm using 
a digital Vernier Caliper (Mitutoyo Dial Thickness 
Gauge, Mitutoyo, Japan). The mean and standard 
deviation values were calculated and reported.  Hardness 
was determined by using a Monsanto tablet hardness 
tester (n = 6). The friability of the tablets was tested by 
using Roche friabilator. From each batch 20 tablets were 
taken, weighed and finely triturated. An adequate amount 
of this powder equivalent to 100 mg of the drug was 
accurately weighed and shaken with 150 ml of 0.1N HCl 
for 10 minutes. The mixture was diluted with 0.1N HCl 
to produce 200ml and filtered. 10 ml of the filtrate was 
diluted to 100 ml with distilled water and the absorbance 
was measured at 265 nm. The drug content in the 
formulation was calculated using the standard curve. 
From each batch 20 tablets were taken, weighed together 
and individually for the determination of uniformity of 
weight of tablets. The mean and percent deviations were 
determined 10, 11.  
1.7. In vitro dissolution rate study 
Drug release was assessed by dissolution test under 
the following conditions: n = 6 (in triplicate), USP type 
II dissolution apparatus (Lab India, DISSO 2000) at 50 
rpm in 900 ml of 0.1 N HCL  maintained at 37 ± 0.5˚C. 
The tablet was allowed to sink to the bottom of the flask 
before stirring. Special precaution was taken not to form 
air pockets on the surface of the tablet. Five milliliters of 
the sample was withdrawn by using a syringe filter at 
regular intervals and replaced with the same volume of 
pre warmed (37 ± 0.5°C) fresh dissolution medium. The 
drug content in each sample was analyzed after suitable 
dilution using UV spectrophotometer method at 215 nm 
12, 13.  
1.8. In-vitro release kinetics 
In the model-dependent approaches, the order of 
drug release from matrix systems was described by using 
zero order or first order kinetics. The mechanism of drug 
release from matrix systems was studied by using 
Higuchi diffusion model and Hixon-Crowell erosion 
model. Korsemeyer-Peppas support the drug release 
mechanism for further judgment. The respective 
equations for these models according to Korsmeyer-
Peppas equation, the release exponent ‘n’ value is used 
to characterize different release mechanisms for a dosage 
form with cylindrical shape and summarized 14, 15. 
1.9. Swelling Studies of the tablet 
Swelling study of individual batch was carried out 
using USP type II dissolution apparatus (Basket type, 
Lab India, DISSO 2000). For each formulation batch, 
one tablet was weighed and placed in the stainless steel 
basket of the dissolution apparatus and weighed. The 
basket was then placed in the dissolution beaker 
containing 900 ml of 0.1 N HCl media and rotating speed 
of the basket is 100rpm. The tablets were allowed to 
swell at 37 ±0.5˚C; the basket was periodically weighed 
up to 12hr after removing the excess water on the surface 
with a filter paper. The swelling index was calculated 
using following formula. % Swelling Index = {(Wt) – 
(W0)/ (W0)} x 100. Where, W0 was the weight of the 
tablet before placing into the dissolution basket. Wt the 
difference of the {(basket and tablet weight after time t) - 
tablet weight at the initial time (W0)} 
16
 
1.10. In vitro evaluation of mucoadhesion 
1.10.1. Shear stress method  
The shear stress measure the force that cause a 
mucoadhesive to polysaccharide with respect to the 
mucus layer in directional parallel to their place of 
contact of adhesion. The study was carried out on 3% 
w/v aqueous solutions of isolated polysaccharide. Two 
smooth polished glass blocks of 10×10×0.5 cm were 
selected. One glass plate was fixed on a leveled table 
with an adhesive. To the upper block a thread was tied 
and passed through a pulley at a length of 12 cm. At the 
end of the thread a pan of 3 g weight was attached for the 
addition of weights. A drop of polysaccharide solution at 
a temperature of 250C was kept at the center of the fixed 
block with a pipette, and the movable block was placed 
on it. A load of 100 g was applied such that the drop of 
polymer spread as a uniform film in between the two 
glass blocks. After keeping it for fixed time intervals of 
5, 10, and 15 min, the applied load was removed and the 
weights were added into the pan just sufficient to pull the 
upper movable block or to make it slide down from the 
fixed base block. The sheer stress was expressed in 
gm/cm2. The result was compared with the result of the 
synthetic polymer as reported in literature 17.  
1.10.2. Falling sphere method  
To characterize the mucoadhesive strength, the 
falling sphere method was used .For this purpose a clean 
burette was taken and filled with 10% mucus solution 
and fixed in a stainless steel tube. Mustard grain which 
retained on sieve size # 12 were taken and dipped in 
polysaccharide solution of various concentrations (1 % -
5 % w/v) and then each grain were slowly placed at the 
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top of the mucus layer. Time taken by the grain to fall 50 
divisions in the burette was noted and values were 
tabulated. The result was compared with the result of the 
synthetic polymer in place of isolated polysaccharide as 
reported in literature 18. 
1.11. Ex vivo evaluation of mucoadhesion 
1.11.1. Mucoadhesive strength 
Ex-vivo mucoadhesive strength of levamisole tablets 
was measured by using texture profile analyzer (TAXT 
Plus, Stable Micro Systems, and UK). Fresh goat gastric 
mucosa membrane was obtained from the local 
slaughterhouse and stored in phosphate buffer pH 7.4 
and the experiment was performed within 3 hr of 
procurement of goat mucosa. The mucosal membrane 
was excised by removing the underlying connective 
tissue and was placed on the base of Texture Analyzer. A 
tablet was attached to the stainless steel probe to the 
mobile arm of the texture analyzer with the help of a 
both sided tape. The area of contact of mucosa was 
moistened with 50 µl of simulated gastric fluid. The 
mobile arm was lowered at a rate of 0.5 mm/s until a 
contact with the membrane was made. A contact force of 
1 N was maintained for 60 s, after which the probe was 
withdrawn from the membrane at a 0.5 mm/s to the 
distance of 15 mm. the peak detachment force was 
recorded as mucoadhesive force 19.  
1.11.2. Mucoadhesive time 
The fresh goat stomach mucosa was tied on the glass 
slide with the help of double sided tape and the tablet 
was wetted with 1 drop of 0.1 M HCl (pH 1.2) and 
pasted to the goat stomach mucosa by applying a light 
force with a fingertip for 30 s. The glass slide was placed 
at the bottom of vessel paddle type USP Type-II (Lab 
India, DS 8000) apparatus. The test was performed with 
900 ml of the 0.1 N HCl at 37 ± 100C. After 2 min, a 50 
rpm stirring rate was applied to simulate the stomach 
environment, and tablet adhesion was monitored for 24 
h. The time for the tablet to detach from the goat 
stomach mucosa was recorded as the mucoadhesion time 
20 
1.12. In vivo evaluation of mucoadhesion  
1.12.1. Scintigraphic study   
The in vivo mucoadhesive ability was studied by 
gamma scintigraphy in a healthy rabbit of 2.2 kg 
throughout the study. The total study protocol was 
approved by animal ethics committee GIPS (CPCSEA 
Regn. No.1372/C/10/2013/CPCSEA. Study approval No-
GIPS/IAEC/10). Tc-99 m is most widely used 
radionuclide in nuclear medicine. It has a very short half-
life of 6 h and emits photons but not particulate radiation 
(β rays harmful to tissues). A dose of 6 MBq sodium 
pntatectate(Tc-99m) was incorporated into the tablet 
blend during manufacture to facilitate scintigraphic 
imaging at radioactivity was counted in a well-type 
counter (gamma ray spectrometer: GRS 23C, ECIL) at 
IICB, Kolkata. Then put into the led shell. Optimized 
Levamisole tablet was prepared with polysaccharide and 
radionuclide by melt granulation method in the similar 
way as described in their preparation method. The 
prepared formulation (4mm tablets, weight 80mg) was 
administered to the rabbit by oral feeding tube (tracheal 
tube no 4) with mild local anaesthetic (xylocaine gel 
2%). During the study the rabbit was not allowed to eat 
any food, but water was given ad libitum. Static Imaging 
studies were performed and dosage form was visualized 
using a gamma camera (low energy high resolution 
colorimeter integrated with an ENTEGRA work station) 
by moving the table under the camera at Thakurpukur 
Cancer Research centre (Regional Radiation Monitoring 
Centre, Kolkata) under dual-head gamma camera (GE 
Hawkeyes).The Images were recorded at intervals of 1, 
2, 3, 4, 5, 6, 7 and 8 h. 20 
1.13. Pharmacokinetics study 
In vivo study of TBG polysaccharide matrix tablets 
was performed in healthy rabbits (New Zealand, white) 
of either sex weighing 2.8-3.2 kg. They were given 
access to normal standard diet and tap water ad libitium, 
during the experiment. The animals were housed, two 
per cage in standard rabbit cages maintained at 22 ± 30C 
under 12 h light and 12 h dark cycle. The animals were 
acclimatized at least one week prior to the start of the 
experiment. All rabbits had free access to water 
throughout the study. The animals were divided into two 
groups each consisting of three animals. The first group 
received 25 mg dose of optimized formulation of 
levamisole TBG polysaccharide matrix tablet (F45) by 
oral administration. The second group received the same 
dose of standard levamisole in distilled water. The tablets 
were put behind the tongue to avoid their destruction due 
to biting. The Institutional Animal Ethical Committee 
approved the protocol for this study (CPCSEA Regn. 
No.1372/C/10/2013/CPCSEA. Study approval No-
GIPS/IAEC/10).  Blood samples (1.5 ml) were 
withdrawn from a heparinized catheter placed in the 
marginal vein of the ear before administration and at 
predetermined times, using EDTA as anticoagulant. 
Plasma samples were immediately separated by 
centrifugation at 4000 rpm for 30 min using Remi 
centrifuge and stored at -200C until analysis. Baseline 
plasma samples obtained prior to the tablet 
administration at time 0 served as the blank control for 
each animal. Various pharmacokinetic parameters such 
as peak plasma concentration (Cmax), time at which 
Cmax occurred (Tmax), area under the curve (AUC), 
elimination rate constant (Kel), biological half life (t½), 
absorption rate constant (Ka) and mean residence time 
(MRT), Area under the moment time curve (AUMC) 
were calculated in each case from the plasma drug 
concentration data by using PK solver pharmacokinetic 
software 21. 
1.14. Extended stability studies  
To assess the formulation and drug stability, stability 
studies were done according to ICH guidelines.  The 
optimized formulation of Levamisole (45% TBG 
polysaccharide) was subjected to stability study at 40 ± 
2ºC and 75 ± 5% RH for 30, 60, 90 days. The samples 
were evaluated for physical changes, hardness, friability, 
drug content, mucoadhesive properties and percentage 
drug release during the stability studies 22, 23. 
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2. RESULT AND DISCUSSION 
3.1. Acute toxicity study 
The purpose of this study was to evaluate toxicity 
profile of the Terminalia bellerica gum polysaccharide.  
14 day acute oral toxicity study was performed in Swiss 
albino mice. The LD50 of Terminalia bellerica gum 
polysaccharide were not further studied as it was found 
to be safe up to 2000 mg/kg on 24 h study basis. It was 
observed that the animals fed with the Terminalia 
bellerica gum polysaccharide were found to be healthy. 
The animals were observed for any mortality and 
morbidity (convulsions, tremors, and grip strength and 
pupil dilatation) at an interval of 12 h for 14 days. No 
unusual changes in behavior or in locomotors activity, 
ataxia, and signs of toxicity were observed during the 14 
days period. No differences were found in growth 
behavior between the control and treatment group in 14 
days of study 
3.2. Pre formulation study 
3.2.1. Drug–excipient compatibility study by DSC 
        The DSC curves of levamisole, TBG 
polysaccharide, levamisole-TBG mixtures and 
combination of three are presented in Fig.1 Levamisole 
exhibited a single melting endothermic peak 
corresponding to the melting of the drug. Onset of 
melting of Levamisole was observed at 235.23˚C. Any 
sign of interaction would be reflected by a change in 
melting endothermic of levamisole. The results from 
DSC study confirmed that there was no significant 
change in the melting endotherm of levamisole in the 
mixture with TBG polysaccharide as it moves to 
203.79˚C which was not significant for considering as 
prominent drug excipient interaction. Hence, there was 
no well defined chemical interaction between drug and 
polysaccharide 7 
 
 
Figure 1: Combine DSC thermogram of Levamisole, Terminalia bellerica Polysaccharide & polysaccharide & 
Levamisole mixture 
 
3.2.2. Drug–excipient compatibility study by FT-IR 
spectroscopy 
          The FTIR spectra of pure drug levamisole, TBG 
Polysaccharide and levamisole-TBG mixture are shown 
in Fig.2. The FTIR spectrum of levamisole showed peak 
at 2631.69cm–1 due to C=N stretching, peaks at 1572.48, 
1519.44 & 1435.14cm–1 due to C=C (aromatic) 
stretching, 1201.33 cm–1 due to C-N stretching, 734.99 
cm–1 due to C-S, 1964.92 cm–1 due to S (=O) 2 
asymmetric stretching and 838.17 cm–1 due to C-Cl 
symmetric stretching confirming the drug structure.   
 
 
Figure 2: FTIR Spectrum of Levamisole, Polysaccharide and Levamisole-polysaccharide mixture 
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The FTIR spectrum of TBG polysaccharide shows Peaks 
at 969.40 and 831.75 are due to finger print regions for 
carbohydrates, the absorption peaks at 1604.43 cm-1 and 
1412.15 cm-1 are indicative of acetyl group. The absence 
of significant aromatic stretches in the 1600-1690 cm-1 
region and the weakness of the stretches imply that there 
is modest amount of cross linking by peptides. The FTIR 
spectrum of mixture of the tablet showed all the 
characteristic peaks of levamisole indicating the 
undisturbed drug in the formulation. All the peaks of 
TBG Polysaccharide remain unchanged in the physical 
mixture.  The results from FTIR spectroscopy showed 
that there was no significant change in the FTIR 
spectrum of levamisole in mixture with TBG 
Polysaccharide (Fig.2). 
3.3. Evaluation of physical parameters of tablets 
The tablet thickness of the various formulations was 
found to be in the range of 2.62 ± 0.076 to 2.92 ± 0.067. 
The hardness of all tablet were in the range of 3.5 ± 0.3 
to 7.2 ± 0.4 kg/cm2. Hardness increased as the amount of 
concentration of TBG Polysaccharide increased. This 
indicates the binding potentiality of the polysaccharide. 
The tablets prepared in each batch were found to have 
within the limit of weight variation and content 
uniformity. The content of each individual preparations 
were found to be within the limits of 85-115%.  
3.4. In vitro drug release study of all batches 
The in vitro drug release profiles are shown in Fig.3. 
The results indicated slow and controlled release of 
levamisole from the matrix tablet. In the formulations, 
release of levamisole in the first hour varied between 
15.13±0.51 in F10 and 5.06±0.47 in F45. The release of 
drug extended from 10hr in F25 to more than 12hr in 
F40, F45 and F50 batches. The total amount of drug is 
released within 6-7hr from the batches F10 to F20.  The 
drug release decreases when the TBG concentrations 
have increased. Batch F25 also had a controlled pattern 
of drug release but not so significant as compared to the 
other five bathes. Among the five batches (F30-F50) the 
F45 showed mean release of 11.96% drug in first 2hr, 
while within the first 6hr and 8hr mean release were 
69.79% and 74.44%, remaining portion of drug  was 
released during last 4 hr of observation and yet 4.69% of 
drug remain in the formulation. The dissolution for the 
first 12 hr period of F45 batch is steady till the polymer 
relaxation gets predominant. A controlled release pattern 
of drug was observed from the tablets of batch F45 
throughout the 12 hr of dissolution study. Hence, F45 
batch was selected as the optimized batch for further 
stability and pharmacokinetic study. 
 
 
Figure 3: Comparative dissolution drug profile of all batches (Mean value ± SD) 
3.5. Kinetics and mechanism of drug release 
The release rate constant was calculated from the 
slope of the appropriate equations and the correlation 
coefficient (R) was determined for all formulations 
(Table-2). In most of the formulated tablets the R values 
were higher in first order model than in zero order 
models indicating that the drug release from most of the 
tablets followed first order kinetics. Determination of 
correlation coefficient from various formulations, 
containing different proportions of TBG Polysaccharide 
indicates that first-order and Korsemeyer–Peppas 
equations seemed to be better fit than other equations. 
The R values of 0.980, 0.981, 0.965, 0.975, 0.959, 0.950, 
0.981, 0.998, 0.937 for the batches of tablets F10, F15, 
F20, F25, F30, F35, F40, F45 and F50 respectively 
which showed good linearity between log cumulative 
amount of drug release versus log time. The n values 
were found to be 0.728, 0.861, 0.908, 0.824, 0.802, 
0.842, 0.917, 0.828, and 0.763 for the tablets F10, F15, 
F20, F25, F30, F35, F40, F45 and F50 respectively. 
Hence, the mechanism of drug release from the tablets 
was predicted from Korsemeyer–Peppas equations and 
from the obtained n values was a coupling of both the 
process of diffusion and erosion. 
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Table 2: Release Kinetics study of formulated baches of TBGP mucoadhesive matrix tablets 
Model Parameters Formulation Code 
  F10 F15 F20 F25 F30 F35 F40 F45 F50 
Zero Order R² 0.941 0.973 0.961 0.957 0.935 0.936 0.938 0.932 0.901 
K0 0.356 0.284 0.226 0.179 0.151 0.143 0.142 0.148 0.152 
First Order R² 0.968 0.946 0.919 0.955 0.948 0.938 0.913 0.937 0.941 
K1 0.007 0.005 0.004 0.003 0.003 0.002 0.002 0.003 0.004 
Higuchi R² 0.937 0.897 0.856 0.890 0.879 0.856 0.820 0.860 0.872 
KH 5.21 4.47 3.93 3.48 3.21 3.02 2.98 3.13 3.27 
Hixon-Crowel R² 0.985 0.970 0.949 0.977 0.969 0.957 0.937 0.957 0.958 
KHC 0.002 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 
Korsemayer – 
Peppas 
R² 0.980 0.981 0.965 0.975 0.959 0.950 0.981 0.998 0.937 
KKP 1.563 0.621 0.387 0.521 0.517 0.382 0.239 0.432 0.668 
Release 
Exponent (n) 
0.728 0.861 0.908 0.824 0.802 0.842 0.917 0.828 0.763 
 
3.6. Swelling study 
Appropriate swelling behaviour of mucoadhesive 
tablet is very much essential for uniform prolong release 
of the drug and effective mucoadhesion .The percentage 
of swelling ranging from 15.2±4.6% to 20.1±3.8 in first 
hour but increases over 200% in 10-12 hr. Some tablet 
shows decrease amount of swelling between 10 -12 hour 
because of erosion and breaking occurred in 10-12 hour. 
When the concentration of the polymer increases, 
swelling increases with time which has been showed in 
(Fig 4).  
 
 
Figure 4: Swelling index of the tablet 
3.7. In vitro mucoadhesive property 
3.7.1. Shear stress method 
The bioadhesion of the formulations was measured 
in vitro as a detachment force measurement, or the force 
required detaching the formulation from the mucosal 
tissue. After each measurement, the tissue was replaced 
by fresh piece and finally detachment force was 
measured. The amount of shear in gram increases as the 
holding time increases. After 5, 10 and 15 minute the 
detachment weight requirement was 11.78 ± 0.48gm, 
32.90±0.32 and 84.73±0.26 respectively. This result is 
comparable to the result reported in literature for 
synthetic polymer 23. This indicates that higher holding 
time requires the most maximum force in grams to break 
the bond between the polysaccharide and the mucosal 
surface. Further, the wetting time is more as the holding 
time increases and the carboxylic acid structure in 
polysaccharide gradually undergo hydrogen bonding.    
3.7.2. Falling sphere Method 
In vitro mucoadhesive property of the TBG 
polysaccharide was evaluated by falling sphere method. 
It was observed that as concentration of the 
polysaccharide was increased, resistance in terms of time 
to move of the mustard towards bottom side was also 
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increased. Time in seconds required to move the mustard 
grain from top to bottom in 5 % w/v solution was found 
to be 67.353 ± 0.34 Seconds. This indicates that higher 
the concentration of the polysaccharide increases the 
adhesiveness of the polysaccharide containing mustard 
and decreases the downward movement. This result is 
comparable to the result reported in literature for 
synthetic polymer 18.  
3.8. Ex-vivo evaluation studies 
3.8.1.  Mucoadhesive strength studies 
The result depicts an increase trend in mucoadhesive 
strength, with an increase in the TBG Polysaccharide 
concentration. After each measurement the tissue was 
replaced by fresh tissue, the tissue was replaced by fresh 
piece and finally detachment force was measured. The 
mucoadhesive strength was increased from 19.4 ± 0.51N 
to 73.6 ± 1.07 N at low and high level of isolated 
polysaccharide. Increasing the polymer amount provides 
more adhesive sites and polymer chains for 
interpenetration with mucin, resulting in augmentation of 
bioadhesive strength 24.   
3.8.2. Mucoadhesive time studies 
The residence time of the formulations ranged 
between 106 min and 490 min. The results showed that 
the mucoadhesive time is concentration dependent. 
Increasing contact time may provide inter diffusion and 
chain entanglement between the polysaccharide and 
mucin chain in mucus membrane. This is in agreement 
with Leung and Robinson, who demonstrated that 
mucoadhesion of carbomer was a time dependent process 
supporting the proposed interpenetration as being a time 
dependent process 25. An increase in contact resulted in 
an increase in formation of secondary bonds and 
diffusional path or depth of interpenetration between two 
macromolecules. Increasing contact time between the 
mucoadhesive polysaccharide and the mucus layer could, 
therefore, increase the mucoadhesive strength.  
3.8.3. Scintigraphic study   
The scintigraphic method was adopted to monitor 
the system in the gastric region of rabbit in different time 
interval. The selected scintigraphic images of the 
formulation at different time intervals are presented in 
Fig. 5. From the scintigraphic images, it can be observed 
that stagnation of the formulation took place in between 
stomach and upper portion of the small intestine. The 
scintigraph clearly explained that the liberated 
radioactivity was distributed across the whole stomach of 
the rabbit indicating the mucoadhesive action of the 
polysaccharide. The scintigraphic image taken after 1 hr, 
2 hr, 3 hr, 4 hr, 5 hr, 6 hr, 7 hr and 8 hr revealed that the 
formulation remains intact in the stomach at the end of 8 
hr by adhesion in the mucus membrane. The result is 
comparable with the results of studies in vivo in animals 
relating to mucoadhesion of polymers 26. 
 
 
Figure 5: Scintigraphic image of rabbit showing mucoadhesion of Terminalia bellerica matrix tablet 
 
3.9. In vivo plasma concentration-time data 
The mean pharmacokinetic parameters of the 
optimized formulation and standard levamisole 
formulation (Levasol-50), (Cmax, Tmax, Ka, Kel, AUC0-t, 
AUC0-∞, t 1/2 and MRT0-t, and AUMC) calculated from 
the individual plasma concentrations of the in vivo 
experiments are represented in Table 3. The mean 
plasma concentration-time curves of optimized 
formulation with compare to standard formulation 
following oral administration are given in Fig. 6. The 
absorption of levamisole is rapid in standard formulation 
than the test; the mean Tmax was 3.17 hr, while in the 
optimized tablet containing TBG polysaccharide, the 
mean Tmax was delayed by more than 6.19 hr. This shows 
that the mucoadhesive TBG Polysaccharide tablet was 
effective in delaying the peak plasma concentration of 
levamisole. The peak plasma concentration (Cmax) of 
levamisole standard formulation and optimized 
formulation were found to be 5.33 and 5.63 μg/ml 
respectively. The Kel values were found to be 0.15 and 
0.30 hr-1 calculated from the slope of the terminal phase 
of the plasma concentration time data. A decrease in 
elimination rate constant of optimized formulation 
indicated the slow release rate of the drug in rabbit 27.   
The plasma t1/2 values of levamisole matrix tablet of 
optimized formulation and standard levamisole tablet 
were found to be 4.63 and 2.31 hr respectively. The 
controlled release characteristics of the matrix tablet 
were reflected in the MRT. The MRT was noticeably 
increased following oral administration of the levamisole 
matrix tablet of optimized formulation (12.63 hr) as 
compared to levamisole standard tablet (6.35 hr). The 
Das et al                                      Journal of Drug Delivery & Therapeutics; 2014, 4(4), 24-33 32 
© 2011-14, JDDT. All Rights Reserved                                       ISSN: 2250-1177                                   CODEN (USA): JDDTAO 
AUC0-t of levamisole standard tablet was found to be 
54.20 μg.hr/ml, whereas increase in AUC0-t was observed 
in optimized formulation (86.42 μg.hr/ml), which 
indicated the increased bioavailability of the optimized 
formulation. The other parameters viz AUC0-∞, AUMC 
were also found to be much higher in the levamisole 
matrix tablet of optimized formulation. Significant 
difference was observed in all the pharmacokinetic 
parameters between both the formulations. Thus, the 
results of the present study clearly indicated the 
applicability of polysaccharide for the in vivo sustained 
release of the levamisole. 
 
Table 3 - Pharmacokinetic parameters Optimized Mucoadhesive levamisole tablet of test TBGP 45%and 
standard levamisole formulation in healthy animals 
Parameter Unit TBGP 45% Standard formulation  
Tmax H 6.19±0.14 3.17±0.03 
Cmax μg/ml 5.63±0.23 5.33±0.07 
Kel hr
-1 0.15±0.01 0.30±0.03 
Ka hr
-1 0.16±0.006 0.32±0.002 
t1/2 hr 4.63±0.31 2.31±0.06 
AUC0-t μg.hr/ml 86.42±2.60 54.20±0.82 
AUC0-∞ μg.hr /ml 96.88±4.09 54.45±0.84 
AUMC μg /ml.hr
2 1225.63±99.26 346.13±7.99 
MRT Hr 12.63±0.46 6.35±0.07 
The results are mean±s.d 
 
 
Figure 6: Mean plasma concentration vs. time profile of Test (F45) and standard (levasol-50) 
3.10. Extended stability study  
Extended stability study of the optimized 
mucoadhesive tablets levamisole (F45) were carried out 
under proper condition for 90 days. There was no 
significant change in the percentage of hardness, 
friability and of the amount of drug content as well as in 
mucoadhesive strength after 30, 60 & 90 days mentioned 
in Table 4.  Based on the result it was opined that the 
tablets of batch F45 were stable after 3 months of storage 
at accelerated stability conditions. 
 
Table 4: Extended stability study of Optimized Levamisole Tablet (45% TBG polysaccharide). 
 Optimized formulation (F45) 
Parameters After30 Days After 60 Days After 90 Days 
    
Hardness (Kg/cm2) a 3.2±0.35 3.8±0.2 3.85±0.15 
Friability (% w/w) b 1.55±0.12 1.40±0.15 1.95±0.15 
Uniformity of Weight (mg) b 157.87±1.01 161.20±2.99 163.57±1.20 
Uniformity of Content 
(% w/w) b 
97.16±0.12 95.15±0.61 94.15±0.25 
Mucoadhesive Strength(N) 34.19±1.91 29.95±0.92 20.33±0.93 
 
4. CONCLUSION 
From the present study, conclusion was focused on 
the formulation of 12 hr mucoadhesive controlled release 
tablets of levamisole using Terminalia bellerica gum 
polysaccharide as matrix forming hydrophillic polymer. 
It was summarized from the dissolution studies that the 
tablets containing less concentration of Terminalia 
bellerica gum polysaccharide were disintegrated readily 
but at higher concentration of Terminalia bellerica gum 
polysaccharide the tablets released the drug in a 
controlled manner over 12 h. The study of release 
mechanism exhibited anomalous non-fickian diffusion 
that involved both diffusion and erosion mechanisms. 
Among all the formulations, the F45 batch exhibited 
optimum drug release profile and significant 
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mucoadhesive properties. The pharmacokinetic study of 
the optimized batch (F45) in rabbits was carried out in 
triplicate. The plasma drug concentration versus time 
interval was estimated by using in house developed 
HPLC method procedure. The optimized controlled 
release tablets exhibited first order absorption rate 
kinetics in the release of drug from the tablets. The 
increase in Tmax value and decrease in Cmax value in 
case of the optimized formulation F45 from the values of 
the conventional tablet of levimasole revealed that the 
TBG polysaccharide can be used as carrier for 
developing mucoadhesive formulations.  
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